If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
236
results.
Updated on
13/07/2025 [06:53:00]
Results 25 to 50 of 236
Absstract of: CN120284906A
本发明公开了一种包载七叶皂苷钠的纳米粒子及其制备方法与应用，制备方法包括以下步骤：七叶皂苷钠和阳离子单体在引发剂和交联剂的作用下进行自由基聚合反应，得到所述包载七叶皂苷钠的纳米粒子。本发明制备得到的包载七叶皂苷钠的纳米粒子，将七叶皂苷钠与ROS响应型纳米粒子结合，构建了基于纳米递送系统的肠道靶向制剂，能够在炎症高发且ROS水平升高的肠道部位响应性释放药物，提高了药物的局部浓度和治疗效果，有效解决了七叶皂苷钠口服生物利用度低的问题，还能有效减轻其毒性，提高临床应用的安全性，在制备治疗溃疡性结肠炎药物方面展现出广阔前景。
Absstract of: CN120285169A
本申请涉及生物医药技术领域，公开了一种广谱抗肿瘤经皮免疫mRNA疫苗及其制备方法。所述广谱抗肿瘤经皮免疫mRNA疫苗包含诱导多能干细胞与肿瘤共享抗原的基因序列，其药用载体为树突细胞靶向性脂质纳米颗粒，所述mRNA分子封装于所述脂质纳米颗粒中。所述共享抗原包括氨基酸序列为SEQNO:1‑14的抗原。本发明基于肿瘤细胞‑iPSC共享新抗原构建具有广谱肿瘤预防性的mRNA经皮免疫疫苗，有望实现更理想的应用效果，且使用便捷安全、工艺简单，利于推广。
Absstract of: WO2025146088A1
The present invention relates to a nanomaterial for preventing tumor bone metastasis, a preparation method therefor, and use thereof. The present invention has discovered a spatiotemporal coupling interaction between tumor cells and osteoclasts, and provides a tumor-bone initial metastasis behavior-targeting strategy which can accurately prevent tumor metastasis on the basis of the source, and can avoid drug resistance and biochemical drug resistance. On this basis, the present invention designs a physical killing nanomaterial targeting tumor-osteoclast conjugates, the nanomaterial being a bone targeting group-modified nanovesicle encapsulating a carbonate compound and a phosphate compound. The nanomaterial can be effectively concentrated in bone tissue; when tumor cells are activated, the acid secretion function of tumor-related osteoclasts in nearby tumor-osteoclast conjugates which are in contact with the tumor cells triggers the carbonate compound to generate carbon dioxide gas and promotes the release of the phosphate compound, which forms calcium phosphate crystals with calcium ions so as to kill nearby tumor cells, thus achieving a specific very-early tumor metastasis inhibition effect.
Absstract of: WO2025146125A1
Disclosed in the present application are a compound having a structural formula as represented by formula (I), and a salt and an isomer thereof. Further disclosed in the present application is a nanoparticle composition containing the compound, or the salt thereof or the isomer thereof. The nanoparticle of the present application can efficiently deliver a drug or a vaccine into cells to exert the therapeutic or preventive purpose of the drug or the vaccine.
Absstract of: WO2025146614A1
A nanofiber-based skin patch for alleviating pain, swelling, and inflammation comprising a skin adhesive layer, a nanofibrous layer comprising at least one macromolecule and a composition of natural active agents comprising a mint extract, a rose madder extract, a rosemary extract, a lavender extract, a clove extract, an arnica extract, a ginger extract, a sage extract, a ginseng extract, a garlic extract, curcumin, bromelain, honey, royal jelly, propolis, a non-woven layer configure to connect the nanofibrous layer to the skin adhesive layer such that the nanofibrous scaffold is fabricated on a top surface of non-woven layer, and a protective layer configure to protect the nanofibrous layer. The developed nanofiber-based skin patch can relieve pain, reduce swelling, and mitigate inflammation in different areas of a subject's bod without causing side effects.
Absstract of: WO2025146681A1
The present invention relates to pro-nano-emulsion compositions comprising at least one type of Omega 3 fatty acid capable of converting to nano-emulsion composition having average droplet size of below Ip, typically below 0.5p, and use thereof, particularly as dietary supplement, for preferential delivery of the Omega 3 fatty acid to heart and/or liver tissue of a subject consuming the composition, thereby maintaining normal cardiovascular/hepatic function and/or improving cardiovascular/hepatic disease or disorders.
Absstract of: WO2025147134A1
The present invention relates to a nanodisc comprising a virus receptor and a FC fragment. In addition, the present invention relates to a pharmaceutical composition for prevention or treatment of viral infection, the composition containing the nanodisc. In the present invention, the nanodisc comprising a virus receptor and a FC fragment of the present invention has been confirmed to have a long in vivo half-life while also exhibiting excellent antiviral efficacy.
Absstract of: WO2025147516A1
The present invention provides a lipid nanoparticle comprising an entity that contains one or multiple sialic acid (SA) moieties, the entity is preferably a ganglioside, a ganglioside derivative, a ganglioside mimetic, or a combination thereof. The lipid nanoparticle of the present invention can effectively present SA moieties on the surface to bind Siglecs and complement factors to, inter alia, mitigate inflammation. The present invention also provides methods of using said lipid nanoparticle compositions described herein for pharmaceutical applications. For example, the lipid nanoparticles provided herein are useful for treating inflammatory and autoimmune diseases.
Absstract of: WO2025147528A1
The present invention is based on the surprising discovery that a lipid nanoparticle (LNP) bearing sialic acid residues on the surface can withstand nebulization and maintain its integrity. The invention provides an LNP composition comprising a lipid bearing, or substituted by, a sialic acid (SA) residue such as a ganglioside, a ganglioside derivative, a mimetic, a SA-bearing entity or a combination thereof. The lipid nanoparticles described herein can incorporate nucleic acid molecules, or cargos, withstanding nebulization, and delivering the cargos to the lung via a nebulization-mediated delivery. The present invention also provides methods of using the LNP compositions described herein for pharmaceutical applications. For example, the LNPs provided herein are useful for the treatment of various pulmonary diseases. The LNPs provided herein are also useful for prophylactic applications including vaccines for infectious diseases, allergies, autoimmune diseases and cancer.
Absstract of: WO2025147545A1
The present disclosure relates to compositions comprising lipid nanoparticles for delivering nucleic acid molecules into cells. Also included are methods for producing and using such compositions.
Absstract of: US2025222019A1
The present disclosure provides a C6′-substituted locked nucleic acid-modified cap analog and a use thereof, wherein the cap analog improves the stability of mRNA and/or the translation efficiency of mRNA.
Absstract of: WO2025147604A1
A composition for genetic editing of a hydroxyacid oxidase 1 (HAO1) gene, comprising: (a) a messenger RNA (mRNA) encoding a Cas12i2 polypeptide, (b) a guide RNA (gRNA) targeting the HAO1 gene; and (c) lipid excipients, which optionally form lipid nanoparticles. Also provided herein are methods for genetic modification of the HAO1 gene in host cells with the composition provided herein.
Absstract of: US2025222113A1
This application relates to lipid nanoparticles, which include: a helper lipid and an ionizable lipid, at least one lipid layer surrounding an interior having at least one aqueous portion, an encapsulated inorganic particle, and an agent of interest (e.g. therapeutic, diagnostic, or theranostic agents). The ionizable lipid is present at between 2 mol % and 30 mol % relative to total lipid. The agent of interest is a hydrophilic agent present in the at least one aqueous portion or is a lipophilic agent present in the at least one lipid layer. This application also relates to methods of making the lipid nanoparticle, as well as methods of using the lipid nanoparticle (e.g. for therapy or diagnostics), including using external stimuli (e.g. laser irradiation) to release the agent of interest.
Absstract of: US2025222097A1
The present disclosure relates to compositions comprising RNA and a cationically ionizable lipid for delivering RNA to target tissues after administration, in particular after parenteral administration. The present disclosure also relates to methods for delivering RNA to cells of a subject or for treating or preventing a disease or disorder in a subject, wherein the methods comprise administering to a subject a composition of the present disclosure. Furthermore, the present disclosure also relates to methods for delivering a pharmaceutically active peptide or protein to a subject or for treating or preventing a disease or disorder in a subject, wherein the methods comprise administering to a subject an RNA composition of the present disclosure, wherein the RNA encodes the pharmaceutically active peptide or protein.
Absstract of: US2025222129A1
The present document describes a pharmaceutical composition comprising a) a lipid nanoparticle operable to encapsulate a therapeutic agent, comprising a core and an external surface, said therapeutic agent being encapsulated within said core; said lipid nanoparticle having a size of said lipid nanoparticle of from about 30 to about 80 nm, or a pegylated lipid comprising a distearoyl-rac-glycerol (DSG)-PEG and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(DSPE)-PEG-DBCO; or a combination of: a size of from about 30 to about 80 nm and a pegylated lipid comprising a DSG-PEG and DSPE-PEG-DBCO; and b) an antibody or antigen-binding fragment thereof operable to transmigrate the blood-brain barrier (BBB), wherein the antibody or antigen-binding fragment thereof comprises complementarity determining regions (CDR1, CDR2 and CDR3), operably linked to said external surface of said lipid nanoparticle.
Absstract of: US2025222094A1
The present application relates to a polynucleotide molecule that can be used for preventing or treatment HPV infection-related diseases, and a pharmaceutical product, a pharmaceutical composition, or an mRNA vaccine comprising said polynucleotide.
Absstract of: US2025222126A1
The present disclosure relates to DNA-peptide hybrid molecules. In some embodiments, the DNA-peptide hybrid molecules comprise target-specific binding peptides which selectively bind to a target molecule. Methods of using DNA-peptide hybrid molecules in the treatment of diseases or disorders are also provided.
Absstract of: US2025222130A1
An antibacterial nanoparticle (ANP) and related methods and antibacterial medical products are disclosed. An ANP includes a silica core with a plurality of gold nanospheres conjugated thereto and at least some of the gold nanospheres being silver-coated gold nanospheres. Iron oxide nanospheres may also be conjugated to the silica core, and at least some of the silver-coated gold nanospheres, or iron oxide nanospheres, if present, can be conjugated to one or more polycationic polymers and/or one or more antibacterial peptides.
Absstract of: US2025221931A1
This disclosure relates to mRNA therapy for the treatment of Fanconi anemia and related diseases, disorders or conditions. mRNAs for use in the invention, when administered in vivo, encode a Fanconi anemia, complementation group (FANC) protein such as FANCA, FANCC, or FANCG. mRNA therapies of the disclosure increase and/or restore deficient levels of a FANC protein such as FANCA, FANCC, or FANCG expression and/or activity in subjects.
Absstract of: US2025221945A1
This invention discloses a curcumin self-dispersing particle system, its preparation method and apparatus, and application. This system allows poorly soluble or insoluble compounds to form controllable, uniformly distributed crystalline particles that self-disperse in aqueous solutions, significantly enhancing solubility and imparting micro-nano properties. It enables categorized combinations of multiple compounds for diverse systems suitable for pharmaceutical applications like combination therapy, synergistic enhancement, and combating drug resistance. The system boasts simple, rapid production, broad applicability, and suitability for industrial production and clinical translation.
Absstract of: US2025221943A1
The present invention relates to polydopamine co-polymer nanoparticles as defined in the application. The present invention also relates to processes for the preparation of these polydopamine co-polymer nanoparticles, to pharmaceutical compositions comprising them, and to their use in therapy.
Absstract of: US2025221930A1
The present invention relates to a composition comprising an aqueous phase, a polyene antifungal and lipid nanoparticles which are dispersed in the aqueous phase, said lipid nanoparticles comprising an oily internal phase and an envelope, the envelope comprising a polyglycol ester of a hydroxy fatty acid, the polyene antifungal being dispersed in the aqueous phase and/or being part of the lipid nanoparticles. It further relates to lipid nanoparticles comprising an antifungal polyene, an oily internal phase and an envelope, the envelope comprising a polyglycol ester of a hydroxy fatty acid and the polyene antifungal being part of the lipid nanoparticles, and preparation method thereof. It also relates to the composition or lipid nanoparticles of the invention for use in the prevention or treatment of an infection caused by a fungus, preferably a fungus of the Mucorales order.
Absstract of: US2025221925A1
Provided herein are methods and compositions for trans-tympanic membrane delivery of therapeutic agents such as antimicrobial agents, anti-inflammatory agents, and anti-biofilm agents to the middle or inner ear for rapid, localized treatment and prevention of diseases and conditions associated with a middle ear infection. In particular, provided herein are anionic and polymer-based nanoparticles that provide a platform for delivery of therapeutic cargo, as well as anionic and polymer-based nanoparticle compositions for rapid, localized delivery of therapeutic agents to the middle or inner ear.
Absstract of: US2025221936A1
Described herein are engineered hemichannels, engineered vesicles that can contain the one or more of the engineered hemichannels, pharmaceutical formulations thereof, and uses thereof. In some aspects, the engineered vesicles can include one or more cargo molecules. Also described herein are methods of loading the engineered vesicles. In some aspects, loading of one or more cargo molecules engineered vesicles can be optionally via an engineered hemichannel contained in the engineered vesicle.
Nº publicación: US2025221935A1 10/07/2025
Applicant:
LAWRENCE LIVERMORE NAT SECURITY LLC [US]
THE REGENTS OF THE UNIV OF CALIFORNIA [US]
LAWRENCE LIVERMORE NATIONAL SECURITY, LLC,
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Absstract of: US2025221935A1
Nanolipoprotein particles having at least a scaffold protein component and a membrane lipid component and related compositions, methods and systems are described. The membrane lipid component includes at least one or more membrane forming lipids, one or more polymerized lipids and/or one or more polymerizable lipids.
BOPI
Electronic site
